4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Myasthenia Gravis by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 331 ongoing clinical trials involving Myasthenia Gravis
Of the 331 trials,247 trials are in Phase III
Furthermore, 36 trials are in Phase II/III

Number of ongoing Clinical Trials (for drugs) involving Myasthenia Gravis by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Myasthenia Gravis, an immunology indication. The largest number of ongoing clinical trials for Myasthenia Gravis is conducted in Europe. Asia-Pacific and North America are among some of the other prominent regions engaged in Myasthenia Gravis-related drug trials.

Argenx SE: The leading ongoing Myasthenia Gravis related clinical trial sponsor

Argenx SE is the top sponsor for Myasthenia Gravis-related ongoing clinical trials.

Alexion Pharmaceuticals Inc, Xuanwu Hospital Capital Medical University, Aarhus University, UCB SA, Ra Pharmaceuticals Inc, and Johnson & Johnson are among other notable clinical trial sponsors involved in Myasthenia Gravis. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Myasthenia Gravis

Eculizumab (Soliris), Tacrolimus (Modigraf, Prograf, Prograft), and Methylprednisolone (Solu-Medrol, Depo-Medrol, Medrol, Medrate, Depo-Medrate, Medrol Acetate, Solu-Medrone, Solu-Moderin, Depo-Medrone, Methylprednisolone Sodium Succinate, Promedrol, Medrol A, Medroxyprogesterone Acetate Greenstone) are among the key marketed drugs involving Myasthenia Gravis.

Eculizumab (Soliris) is a humanized monoclonal antibody directed against terminal complement protein C5. It functions via Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) Inhibitor mechanism of action. Soliris is formulated as injectable concentrated solution and injectable solution for intravenous route of administration. Soliris is marketed for the treatment of Myasthenia Gravis and several other indications including Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome), Neuromyelitis Optica (Devic’s Syndrome). Eculizumab was first approved in 2007 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by Alexion Pharmaceuticals Inc and its subsidiaries.

Tacrolimus (Modigraf, Prograf, Prograft) is an immunosuppressive agent. It functions via Calcineurin (Protein Serine/Threonine Phosphatase 3 or Protein Phosphatase 3 or EC 3.1.3.16) Inhibitor mechanism of action. Prograf is formulated as hard gelatin capsules, granules, powder for suspension for oral route of administration and injectable solution for intravenous and intravascular route of administration. Prograf Keytruda is marketed for the treatment of Myasthenia Gravis and several other indications including Lupus Nephritis, Pneumonia, Liver Transplant Rejection, Heart Transplant Rejection, Bone Marrow Transplant Rejection, Lung Transplant Rejection, Ulcerative Colitis, Rheumatoid Arthritis, Crohn's Disease (Regional Enteritis), Kidney Transplant Rejection. Tacrolimus was first approved in 1993 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by Janssen-Cilag Ltd, Astellas Pharma Inc, and their subsidiaries.